BioSpace News Archive

Drug Development

Genentech’s Xofluza Comparable to Tamiflu in Phase III Trial

Genentech, a Roche company, announced that its Phase III MINISTONE-2 clinical trial hit its primary endpoint, showing that its Xofluza (baloxavir marboxil) was comparable to its own Tamiflu (oseltamivir). It was also well-tolerated in children with the flu.

July 3, 2019
·
2 min read
·
Mark Terry
Drug Development

Unum Plunges After FDA Places Another Clinical Hold on Company Asset

The latest clinical hold was placed after a patient experienced serious adverse events that included neurotoxicity and cytomegalovirus infection, as well as severe respiratory distress.

July 3, 2019
·
2 min read
·
Alex Keown
Drug Development

Research Roundup: Gut Bacteria to Prevent and Reverse Food Allergies and More

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

July 3, 2019
·
4 min read
·
Mark Terry
Policy

Social Media Sites Cracking Down on Misleading Medical Claims

Facebook, YouTube and other sites are changing protocols regarding posts that contain information about misleading medical treatments.

July 3, 2019
·
2 min read
·
Alex Keown
Career Advice

Health Insurance 101 for Life Science Professionals

A recent BioSpace survey found that health insurance is one of the top considerations of life science professionals willing to relocate for a job. To learn more, we interviewed Carrie Richards Leary, a health insurance benefits professional.

July 3, 2019
·
4 min read
·
Porschia Parker
Deals

Evotec completes acquisition of Just Biotherapeutics

Evotec SE announced that the strategic transaction to acquire Just Biotherapeutics, signed on 20 May 2019, has been completed.

July 3, 2019
·
5 min read
Business

Confo Therapeutics and DyNAbind announce drug discovery collaboration to identify novel GPCR-modulating compounds

Confo Therapeutics, an emerging drug discovery company, and DyNAbind GmbH announce a drug discovery collaboration on an undisclosed G-protein coupled receptor.

July 3, 2019
·
3 min read
Business

Nosopharm and Evotec enter into collaboration to accelerate development of novel antibiotics

Nosopharm and Evotec SE announce their partnership aimed at advancing Nosopharm’s lead candidate, NOSO-502, to the clinical stage, as well as developing a second-generation Odilorhabdin drug candidate.

July 3, 2019
·
4 min read
Drug Development

Auris Medical Completes Enrollment of Phase 1b Proof-Of-Concept Trial of AM-201 in Antipsychotic-Induced Weight Gain

Auris Medical Holding Ltd. announced that it has completed enrollment in its Phase 1b proof-of-concept trial of AM-201, the Company’s investigational drug for the prevention of antipsychotic-induced weight gain and somnolence.

July 3, 2019
·
5 min read
FDA

U.S. Pharma and Biotech Companies Develop Therapies that Lead to ‘Health Independence.’

As fireworks illuminate the night skies across the United States this weekend in celebration of Independence Day, BioSpace takes a look at some of the highlights of the pharma industry from the first half of 2019 and earlier that provides millions of patients with the independence of health.

July 3, 2019
·
4 min read
·
Alex Keown